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Background. Heavy menstrual bleeding (HMB) is a common gynecological complaint affecting quality of life. Objectives. To assess
knowledge on diagnosis and treatments of HMB of Latin American (LA) obstetricians and gynecologists (OBGYNs).Methods. A
survey was conducted during a scientific meeting, organized to provide updated information on topics of reproductive medicine to
OBGYNs from 12 LA countries who were invited to respond to a multiple-choice questionnaire. Results. Of the 210 OBGYNs
participating in the survey, from 169 (80.4%) to 203 (96.7%) answered the questions. Most respondents (80%) gave accurate
answers regarding the amount of blood loss which defines HMB, underreported the proportion of women who consulted due
to HMB, and were aware that the use of combined oral contraceptives (COCs) with ethynyl estradiol is not an adequate treatment
in women with HMB. Female OBGYNs and those who worked in the private sector were more prone to report a higher possibility
of improvement of HMBwith a COC that contained estradiol valerate and dienogest or with a levonorgestrel-releasing intrauterine
system. Conclusions. In general, the respondents were aware of the importance of HMB in gynecological practice and of the new
medical treatments and underreported the proportion of women who consulted due to HMB.
1. Introduction
Menstrual irregularities are a common complaint in gyneco-
logical consultations and heavymenstrual bleeding (HMB) is
one of themost commonmenstrual irregularities reported by
women. HMB has a significant deleterious effect on women’s
quality of life (QofL) and in general increases the num-
ber of consultations and treatments required, consequently
increasing costs of healthcare systems [1]. The worldwide
accepted definition of HMB is a blood loss of >80mL per
cycle [2, 3]; however, the possibility of measuring the exact
amount of blood loss is restricted to research studies due
to the complexity of the techniques [4]. Consequently, in
clinical practice,HMB is defined as “excessivemenstrual blood
loss which interferes with the woman’s physical, emotional,
social, and material QofL and which can occur alone or in
combination with other symptoms” [5].
It has been estimated that almost 18.5% of gynecological
visits in the US and 20% in the UK are due to HMB [6].
Furthermore, in most of the women with HMB, it is not
possible to detect any structural or organic pathology and
even when an endometrial, uterine, or endocrine abnormal
cause is detected, HMB is poorly understood [7].
HMB is a gynecological event that only occurs in women
at reproductive age and consequently many of those women
who need control of the menstrual irregularity also need
contraception. Due to the complexity of the diagnosis and
etiology, at present, therapies for HMB are still under debate
and many still present poor improvement of the medical
condition [7]. The goal of treatments for HMB is to reduce
Hindawi Publishing Corporation
Obstetrics and Gynecology International
Volume 2016, Article ID 6870679, 6 pages
http://dx.doi.org/10.1155/2016/6870679
2 Obstetrics and Gynecology International
menstrual flow and improve QofL. Many women want to
preserve intact uterus due to fertility desire; conservative
medical treatments are frequently preferable to surgical pro-
cedures [8–10].
In most of the Latin American (LA) countries, obstetri-
cians and gynecologists (OBGYNs) are the healthcare pro-
fessionals (HCPs) who are the first line of attention in
women’s health and the main cadre to provide information
and attention on placement and prescription of contracep-
tives. For the reasons above, it is important that OBGYNs
are updated on the importance of HMB within the context
of women’s health, its diagnosis, and treatments in order to
provide adequate counseling and treatment. According to
these considerations, the aim of this report was to assess
some knowledge about diagnosis and treatments of HMB of
a group of LA OBGYNs.
2. Material and Methods
This is the third publication of the data obtained through
a multiple-choice questionnaire completed by LA OBGYNs
using an Interactive Audience Systems Response on occasion
of a scientific meeting in Chile organized by Bayer Health-
Care in the last quarter of 2014 [11, 12]. The OBGYNs came
from 12 countries (Argentina, Bolivia, Brazil, Chile, Colom-
bia, Costa Rica, Ecuador, Guatemala, Mexico, Paraguay,
Peru, and Venezuela). The objective of the meeting was to
discuss updated information on selected themes of women’s
reproductive health related to the use of hormonal and
nonhormonal contraceptive methods and HMB. Data on
knowledge and attitudes regarding unplanned pregnancies
and combined oral contraceptives (COCs) and intrauterine
contraceptives (IUCs) use has already been published [11, 12].
For this paper, questions related to HMB and related health
issues were selected.
All the OBGYNs in this meeting had experience in
providing attention to reproductive health and contraception
in their everyday clinical practice. At the time of registration
for the meeting, all the OBGYNs were invited to take part
in the study and all participants received an explanation
of the objectives of the survey, of the anonymity since the
keypads were only identified with a number, and of the
voluntariness of participation. Those who accepted received
electronic keypads to answer the questions regarding themes
discussed after each lecture and by answering the questions
through the electronic device the OBGYNs were giving their
consent to participate in the study.
The information provided about the survey and consent
of participation and the distribution and collection of the
electronic devices were supervised by one of the researchers
to guarantee the accuracy and uniformity of the procedure.
The study protocol and the procedure for obtaining consent
were approved by the Ethical Committee of the University of
Campinas (UNICAMP), Brazil.
The questionnaire, designed especially for this survey,
contained questions regarding the demographic information
(nationality, age, gender, clinical experience in reproductive
health, and site/location of work (public, private, or both))
of the participants and regarding the knowledge and practice
of the OBGYNs about HMB and health related issues. The
questions were multiple-choice. For each theme discussed
during the meeting, five questions were developed with five
possible answer choices for each question.The questionswere
developed by the researchers who conducted this study and
discussed via e-mail with a group of LA OBGYNs of recog-
nized expertise in the area of HMB who did not participate
in the meeting. To establish the correct answer for each ques-
tion, the group who developed the questionnaire took into
account the LA reality and the treatments used in the region.
Participants had∼3minutes after each presentation to answer
the questions and after that the system automatically locked.
For statistical analysis, the dependent variables were
analyzed taking into account age (≤49, ≥50 years old), gender
(male/female), and the sector in which the OBGYN worked
(exclusively public, both private and public). The statistical
tests used were Pearson 𝜒2, Yates 𝜒2, and Fisher-exact tests.
The software used was SPSS v.20.0. The significance was
established at 𝑃 < 0.05.
3. Results
From the total of 210 OBGYNs participating in the meeting,
responses to the questions on HMB ranged from 169 (80.4%)
to 203 (96.7%) responses. The mean (± standard deviation,
SD) age of the participantswas 48.7± 10.6 (range 30 to 72); 122
(58.1%) were male and 88 (41.9%) were female. Additionally,
112 (55.3%) reported practicing in both the public and the
private sectors and 81 (38.6%) only in the private sector.
The answers of the participating OBGYNs regarding
knowledge on some aspects of HMB are presented in Table 1.
Eighty percent of the respondents were aware of the amount
of blood loss which defines HMB; however, in general, they
were less aware of the proportion of women who consulted
due toHMB. Almost one-third identified endometrial hyper-
plasia as a separate structural abnormality associated with
HMB, and two-thirds of the respondents answered that HMB
is an infrequent and subjective pathology.
Information regarding treatment of HMB is presented in
Table 2. The respondents were aware that the use of COC
with ethynyl estradiol (EE) does not provide adequate relief
of bleeding in women with HMB, although some of them
(between one quarter and one-third) reported higher possi-
bility of improvement of HMB using a COC with estradiol
valerate and dienogest (E
2
Val/DNG) or with the placement
of a levonorgestrel-releasing intrauterine system (LNG-IUS).
4. Discussion
The findings of our study showed that this group of LA
OBGYNs presented somemisconceptions regarding different
specific aspects of HMB. It is worthwhile to note that some
misconceptions persisted among some of the participants.
We observed, in our study, that almost one-third of the
respondents reported that the percentage of women who
consulted for HMB represented more than 20% of the con-
sultations. This reported percentage was higher than those
reported in previous studies [6]. These figures may be
expected if we take into account the total proportion of
Obstetrics and Gynecology International 3
Table 1: Answers provided by the OBGYNs regarding some aspects of heavy menstrual bleeding (HMB).
Age (%) Gender (%) Working in (%)
≤49 ys ≥50 ys Female Male Public sector Private/public sector
What is the proportion of
women who consult due to
HMB? (n = 183)
<5–19% 62.5 60.4 58.1 66.1 67.6 60.0
20–30% 37.5 39.6 41.9 33.9 32.4 40.0
What are your criteria for
diagnosis of HMB? (n = 169)
Bleeding 30–75mL 16.3 30.0 14.9 30.9 32.4 19.1
Bleeding >80mL 83.7 70.0 85.1 69.1 67.6 80.9
The non-structural
abnormalities associated to
HMB are, except for (n = 173)
Hematological disorders,
ovulatory disfunction,
iatrogenic
60.2 74.4 65.7 70.0 68.8 67.9
Endometrial hyperplasia 39.8 25.6 34.3 30.0 31.2 32.1
In your opinion what are the
major challenges to diagnose
HMB at office level? (n = 187)
In clinical practice it is not
possible to measure the
amount of blood loss
35.8 37.5 38.5 35.8 41.7 33.9
The pathology is infrequent
and subjective 64.2 62.5 61.5 64.2 58.3 66.1
Table 2: Answers provided by the OBGYNs regarding some therapeutic aspects of heavy menstrual bleeding (HMB).
Age (%) Gender (%) Working in (%)
≤49 ys ≥50 ys Female Male Public sector Private/public sector
What is the proportion of women
with improvement of HMB with a
COC with EE? (n = 203)
<50% 98.0 79.4 87.1 89.7 86.7 90.0
Up to 80% 2.0 20.6 12.9 10.3 13.3 10.0
What is the proportion of women
with improvement of HMB with a
COC with estradiol Val/DNG? (n =
199)
30–40% 27.7 39.0 27.8 37.7 38.8 29.3
41–79% 41.2 28.4 28.3 35.2 32.3 33.6
>80% 31.1 32.6 43.9 27.1 28.9 37.1
What is the proportion of women
with improvement of HMB with an
LNG-IUS at the end of the first year
of use? (n = 201)
30–79% 75.6 75.6 82.9 70.2 81.6 71.7
>80% 24.4 24.4 17.1 29.8 18.4 28.3
OBGYNs: obstetricians and gynecologists; COC: combined oral contraceptive; EE: ethynyl estradiol; LNG-IUS: levonorgestrel-releasing intrauterine system.
4 Obstetrics and Gynecology International
women who consulted due to menstrual bleeding distur-
bances, but not for consultation regarding HMB [1, 6].
However, it is important to observe that the participant
OBGYNs were aware of the amount of blood loss to diagnose
HMB, although one-third were concerned that the bleeding
amount cannot be measured properly.
Furthermore, more than 50% answered that the disorder
is infrequent. This result is contradictory to previous results
that described that HMB is one of the most common com-
plaints during consultation among women who consulted
due to menstrual abnormalities [6]. It has been described
that HMB has significant effects on women’s quality of life
(QofL) [1, 6, 7, 13]. In a Swedish-based study [13] with
1547 women at reproductive age, the authors evaluated QofL
using the instrument SF-36 in a community-based cross-
sectional web-based questionnaire. The results showed that
32% of the interviewed women presentedHMB.Womenwho
complained of HMB were associated with limited social and
professional activities as well as negative perceptions and
significantly worse health related QofL when compared with
women with normal menstrual patterns in all domains of the
questionnaire. Awareness of OBGYN regarding HMB is an
important issue because early diagnosis and treatment of this
disorder as well as bleeding control could have an important
influence on QofL in this group of women.
HMB is recognized as a worldwide benign, debilitating,
challenging health and social pathology which can cause iron
deficiency. As an example in the United Kingdom, it affects
20–25% of the women at reproductive age which means
that millions of women have either anemia or iron storage
deficiency [14–17]. It is estimated that more than 60% of
women with HMB and blood loss greater than 80mL have
anemia and the incidence increases if blood loss exceeds
80mL. It is worthwhile to take into account the fact that it
has been described that many womenmay complain of HMB
andpresent normal hemoglobin level [18]. Due to the fact that
HMB does not necessarily correlate with anemia, this could
be a possible explanation as to why some women take a long
time before consulting and after consulting in receiving treat-
ment. Consequently, it is important that OBGYNs become
aware of the importance of HMB in clinical reproductive
health practice (with or without anemia) and not only aware
of the symptoms but also aware of the complexity of the diag-
nosis and the fact that HMB may affect women’s QofL [6, 7].
TheOBGYNsparticipating in our studywere less aware of
the abnormalities associated withHMB and almost one-third
answered that endometrial hyperplasia is a nonstructural
abnormality associated with HMB. It was described and
approved by the International Federation of Gynecology
and Obstetrics (FIGO) Executive Board [19] that “structural
abnormalities associated with abnormal uterine bleeding
(AUB) included the PALM-COEIN nomenclature (polyp;
adenomyosis; leiomyoma;malignancy and hyperplasia; coag-
ulopathy; ovulatory dysfunction; endometrial; iatrogenic;
and not yet classified)” and as observed hyperplasia was
included with structural abnormalities.
The use of combined oral contraceptives (COCs) is asso-
ciated with several health benefits and one of them is the
transformation of normal endometrium on a thinner tissue
and consequently the potential effect of treating HMB [20].
The OBGYNs who participated in our study were aware that
the use of monophasic COCs with EE in a 21/7 regimen
presented low effectiveness in the treatment of women with
HMB. COCs are in use worldwide to treat women with acute
and chronic HMB, despite the lack of reliable information
from a randomized clinical trial (RCT) to support the use
[21]. Additionally, Matteson and coworkers recommended
the use of LNG-IUS over COCs, luteal phase progestogens,
and nonsteroidal anti-inflammatory drugs [22]. Presently,
there is limited evidence showing that regular intake of COCs
could provide cycle control and could reduce menstrual
blood loss. Furthermore, due to the fact that COCs also
provide contraception, this could be an acceptable therapy for
women with menstrual disorders [21].
A Cochrane Collaboration review [23] of COCs use
for HMB found only one RCT which met the inclusion
criteria. This RCT, a crossover study of mefenamic acid, low-
dose danazol, naproxen, and a COC (30 𝜇g EE and 150 𝜇g
levonorgestrel (LNG) in a 21/7 regimen), showed similar
results in bleeding control among the various agents tested
on reduction of blood loss [24]. Moreover, in a recent review
[20], COCs were effective in HMB control; however, the
effectiveness was similar to long-term progestin therapy,
superior to short-term progestin therapy, and less effective
than the LNG-IUS. Another therapy in use to treat HMB
is oral tranexamic acid which was reported to be superior
to placebo, mefenamic acid, and progestogen during the
luteal phase [21]. In a double-blind placebo-controlled RCT
with oral tranexamic acid (3.9 g/day for 5 days over 6
cycles), women in the treatment arm presented significant
improvement in blood loss (40.4%) compared with placebo
(8.2%) and improving of QofL [25].
The participants of our survey were aware of the effec-
tiveness of the new COC containing the newer E
2
Val/DNG
regimen. Scientific evidence has proved that such COC is
highly effective in reducing HMB. A study which compared
a COC containing E
2
V/DNG with a COC with EE/LNG for
treatment of HMB showed that women using the E
2
V/DNG
COC presented significantly shorter and lighter uterine
bleeding and fewer bleeding and spotting days than users
of EE/LNG pills [26]. Moreover, it was observed that this
preparation significantly reduced HMB compared to placebo
[27, 28]. Although many women who use COCs can expect
a reduction in the volume of uterine bleeding, physicians
must be aware that different COCs have different effects upon
menstrual cycle bleeding control.
Finally, the participants were aware that one of the
noncontraceptive benefits of the LNG-IUS is HMB control.
It was described that up to 60% of the users presented
improvement in blood loss, hemoglobin, and iron stores and
reduction of anemia up to one year [4, 29]. Furthermore,
women who presented objectively HMB (pretreatment blood
losses between 80mL and 400mL) showed a reduction in
uterine bleeding of 98% at one year after placement of an
LNG-IUS and no woman had an objective blood loss >20mL
after that period of treatment [30]. Due to the body of
evidence about the use of an LNG-IUS in women suffering
fromHMB, the device is approved inmore than 100 countries
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for this purpose and its efficacy is equal or superior to other
therapies [31]. Consequently, LNG-IUS is the first line of
medical treatment for nonorganic HMB in several national
and international guidelines [5] andmanyHCPs consider the
LNG-IUS a first choice for womenwithHMBwith or without
any pathology, with hemostatic disorders, or among women
with uterine fibroids [32].
The study has some limitations.We have information that
all participants had clinical practice in reproductive health
including contraception, but we did not obtain the scientific
profile of the participants or information about work in
academic institutions. The answers they provided could be
influenced by a courtesy bias, mainly the responses regarding
COC and the LNG-IUS, because both products are manufac-
tured by the sponsor of the meeting. Furthermore, due to the
fact that the answers were provided after each lecture, it could
be legitimate to suppose that our results are based on the
participating OBGYNs’ previous training and not necessarily
on baseline attitudes or reaction after each lecture. Also, it has
to be taken into account that the sample size was not esti-
mated in a scientific manner but it was a convenience sample
according to the number of participants in the meeting.
It is important to take into account the fact that HMB is a
gynecological medical condition which affects many women
and requires an understanding of the etiology, diagnosis,
underlying pathologies, and treatments. OBGYNs and other
HCPs must be well capacitated in order to offer to their
patients the best treatments. In conclusion, in this study, we
observed that there was awareness regarding the importance
of HMB in clinical practice; however, some misunderstand-
ings in terms of knowledge of treatments were identified
among LAOBGYNs.This information is important to elabo-
rate strategies and to train and maintain continuous updated
information for LAOBGYN.The fact thatmany of the partic-
ipants reported that HMB is an infrequent and subjective dis-
order could highlight the need for better clinical tools for its
recognition by women and HCPs as well as for its diagnosis.
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